Altaris Completes Acquisition of Simulations Plus and Combination with Chemical Computing Group
October 6, 2026
New York, NY – Altaris, LLC (collectively with its managed funds, “Altaris”) announced today that it completed the acquisition of Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”) and combination with Chemical Computing Group (“CCG”), an existing Altaris operating company. As a result of this transaction, Simulations Plus' common stock has been delisted from the Nasdaq Global Select Market.
The combination of these companies brings together two established, science-led providers of computational tools that will be able to offer biopharma customers a broader spectrum of drug discovery and development solutions.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. Founded in 1996, its software platforms, including GastroPlus, the Monolix Suite, ADMET Predictor, and the QSP/QST platform, are used by every top 20 pharmaceutical company and by contract research organizations (CROs) and regulators worldwide. CCG's flagship product, the Molecular Operating Environment (MOE), is an industry-standard molecular modeling and computational chemistry platform used in the early stages of drug discovery and has been adopted across the global biopharma industry for more than three decades.
Advisors
Truist Securities, Inc. and J.P. Morgan Securities LLC acted as financial advisors to Altaris, and Bass, Berry & Sims PLC and Kirkland & Ellis LLP acted as legal advisors to Altaris. Morgan Stanley & Co. LLC acted as financial advisor to Simulations Plus, and Procopio, Cory, Hargreaves & Savitch LLP acted as legal advisor to Simulations Plus.
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare subsectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com.